Seems people at the summit got a bit of a head start on the news! Hehehe
$Lineage Cell Therapeutics(LCTX.US$ Opregen® (Rg6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Most likely these are the attendees and their companies hahaha
TrytosaveabitOP Jaguar8: More than likely! Hehehe
Airbags : looking good
#buy 